Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2019 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
IMVT on Nasdaq
Shares outstanding
202,731,676
Price per share
$26.27
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
108,608,624
Total reported value
$2,761,160,062
% of total 13F portfolios
0.01%
Share change
+13,571,331
Value change
+$365,973,081
Number of holders
193
Price from insider filings
$26.27
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Roivant Sciences Ltd. 56% -1.8% $2,812,776,314 +$413,666,650 113,327,007 +17% Roivant Sciences Ltd. 12 Dec 2025
FMR LLC 8.4% -17% $237,440,423 -$37,858,433 14,729,555 -14% FMR LLC 30 Sep 2025
Deep Track Capital, LP 5.6% $144,590,000 9,500,000 Deep Track Capital, LP 19 Mar 2025

As of 31 Dec 2025, 193 institutional investors reported holding 108,608,624 shares of Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT). This represents 54% of the company’s total 202,731,676 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) together control 47% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 8.4% 16,990,754 +15% 0.02% $431,904,967
Deep Track Capital, LP 5.7% 11,526,971 +18% 6.7% $293,015,603
VANGUARD GROUP INC 3.8% 7,779,314 +14% 0% $197,750,162
BlackRock, Inc. 3% 6,058,216 +5.6% 0% $153,999,851
ARMISTICE CAPITAL, LLC 2.8% 5,747,155 -1.5% 3.6% $146,092,680
BAKER BROS. ADVISORS LP 2.7% 5,457,881 0% 0.81% $138,739,335
T. Rowe Price Investment Management, Inc. 2.5% 5,060,399 -2% 0.08% $128,636,000
MORGAN STANLEY 2.4% 4,846,384 +147% 0.01% $123,195,110
STATE STREET CORP 1.9% 3,786,926 +31% 0% $96,263,659
RTW INVESTMENTS, LP 1.6% 3,177,850 0.81% $80,780,947
Two Seas Capital LP 1.4% 2,866,962 +3.8% 4.3% $72,878,174
Alpine Global Management, LLC 1.3% 2,627,692 -4.6% 12% $66,770,511
ADAR1 Capital Management, LLC 1.2% 2,480,968 +11% 4.7% $63,066,207
Point72 Asset Management, L.P. 0.99% 2,000,000 -42% 0.08% $50,840,000
PERCEPTIVE ADVISORS LLC 0.98% 1,994,890 +26% 0.93% $50,710,104
Woodline Partners LP 0.97% 1,975,869 +32% 0.19% $50,226,590
GEODE CAPITAL MANAGEMENT, LLC 0.92% 1,857,532 +3.1% 0% $47,226,549
TCG Crossover Management, LLC 0.82% 1,660,933 1.4% $42,220,917
Logos Global Management LP 0.68% 1,375,000 +400% 2.3% $34,952,500
GOLDMAN SACHS GROUP INC 0.64% 1,296,008 -13% 0% $32,944,523
Aberdeen Group plc 0.58% 1,184,122 +21% 0.05% $30,100,381
Soleus Capital Management, L.P. 0.55% 1,110,000 1.2% $28,216,200
PRICE T ROWE ASSOCIATES INC /MD/ 0.44% 893,056 +337% 0% $22,703,000
ADAGE CAPITAL PARTNERS GP, L.L.C. 0.43% 863,000 +151% 0.03% $21,937,460
GREAT POINT PARTNERS LLC 0.37% 750,000 +50% 6.2% $19,065,000

Institutional Holders of Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 108,608,624 $2,761,160,062 +$365,973,081 $25.42 193
2025 Q3 95,145,471 $1,533,747,121 -$22,890,328 $16.12 183
2025 Q2 96,203,927 $1,539,273,430 +$25,954,256 $16.00 167
2025 Q1 94,088,777 $1,608,317,726 +$221,642,111 $17.09 191
2024 Q4 80,137,358 $1,984,988,003 -$10,994,227 $24.77 186
2024 Q3 79,205,377 $2,259,063,728 +$130,270,111 $28.51 182
2024 Q2 74,718,656 $1,972,484,501 +$94,283,095 $26.40 195
2024 Q1 70,316,923 $2,271,922,665 +$28,234,974 $32.31 208
2023 Q4 68,405,672 $2,881,981,571 +$25,897,847 $42.13 227
2023 Q3 68,143,903 $2,616,088,544 +$461,829,770 $38.39 179
2023 Q2 55,460,743 $1,051,890,599 -$33,129,073 $18.97 145
2023 Q1 58,264,079 $903,668,302 +$20,897,901 $15.51 140
2022 Q4 56,538,511 $1,003,523,628 +$261,143,310 $17.75 132
2022 Q3 42,668,627 $238,077,080 +$13,851,662 $5.58 107
2022 Q2 40,117,493 $156,470,492 +$2,266,222 $3.90 87
2022 Q1 39,493,605 $217,710,240 -$1,326,202 $5.51 108
2021 Q4 37,845,291 $322,423,547 -$6,093,696 $8.52 118
2021 Q3 33,769,857 $293,475,463 -$50,043,046 $8.69 115
2021 Q2 38,555,821 $407,535,405 -$67,673,203 $10.57 110
2021 Q1 40,251,421 $645,603,475 -$273,082,395 $16.04 118
2020 Q4 40,331,237 $1,862,979,798 +$41,257,802 $46.19 146
2020 Q3 39,828,501 $1,401,617,459 +$384,378,297 $35.19 116
2020 Q2 28,564,750 $695,567,285 +$388,041,409 $24.35 87
2020 Q1 12,628,676 $193,544,419 +$19,992,364 $15.56 40
2019 Q4 11,331,532 $175,598,863 +$163,278,863 $15.87 24